Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.

Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page
- ChecktodayChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0. This appears to be a metadata/site version change with no visible impact on the study details.SummaryDifference0.0%

- Check36 days agoChange DetectedRevision tag updated to v3.4.3 and the previous v3.4.2 entry was removed.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.4.2 was added and older notices including the government funding lapse notice and Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedAdded a site-wide notice about a lapse in government funding and system status, and updated the page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check80 days agoChange DetectedA glossary toggle has been added to the page to improve terms accessibility. Metadata headers were updated to include 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and the revision version is now v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.